Neutrokine-alpha and neutrokine-alpha splice variant
First Claim
1. The hybridoma of ATCC Deposit Number PTA-1158 or PTA-3794.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.
-
Citations
20 Claims
- 1. The hybridoma of ATCC Deposit Number PTA-1158 or PTA-3794.
-
11. An isolated protein comprising a Neutrokine-alpha protein fused to a toxin protein, wherein said Neutrokine-alpha protein comprises an amino acid sequence selected from the group consisting of:
-
(a) the amino acid sequence of amino acid residues 134-285 of SEQ ID NO;
2;
(b) an amino acid sequence that is at least 90% identical to amino acid residues 134-285 of SEQ ID NO;
2; and
(c) the amino acid sequence of a portion of the polypeptide of SEQ ID NO;
2;
wherein said portion is at least 30 amino acids in length and wherein said portion is capable of stimulating B cell proliferation, differentiation, or survival. - View Dependent Claims (12, 13, 14, 18, 19, 20)
-
Specification